Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1

Prevention strategies for COVID-19 transmission are at the forefront of healthcare paradigms worldwide, the main emphasis of which is vaccination. We present an interesting case of a 37-year-old man who, 3 weeks following his first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Case Rep
Autors principals: Patel, Shreena Umit, Khurram, Ruhaid, Lakhani, Anjali, Quirk, Bernadine
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8070856/
https://ncbi.nlm.nih.gov/pubmed/33888484
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2021-242956
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars